<--- Back to Details
First PageDocument Content
Business / Economy / Biotechnology / American brands / Specialty drugs / CAC 40 / Sanofi / Biosimilar / Biopharmaceutical / Janssen Biotech / Fine chemical / Johnson & Johnson
Date: 2016-06-01 15:33:28
Business
Economy
Biotechnology
American brands
Specialty drugs
CAC 40
Sanofi
Biosimilar
Biopharmaceutical
Janssen Biotech
Fine chemical
Johnson & Johnson

Add to Reading List

Source URL: www.dcat.org

Download Document from Source Website

File Size: 300,36 KB

Share Document on Facebook

Similar Documents

Biotechnology, BS

Biotechnology, BS "DBEFNJD.BQ  5IF"DBEFNJD.BQTFSWFTBTBTVHHFTUFEDPVSTFTFRVFODFPOMZ4UVEFOUTBSFOPUMJNJUFEUPUIJTQMBOJUJTNFBOUUPCFVTFEBT

DocID: 1xTqy - View Document

PDF Document

DocID: 1wroO - View Document

Building A Better Mousetrap:  Patenting Biotechnology In The European Community

Building A Better Mousetrap: Patenting Biotechnology In The European Community

DocID: 1vr7C - View Document

BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod

BIOTECH & PHARMA IN FRANCE KEY FACTS & FIGURES ¾¾ The French biotechnology sector ranks number 3 in Europe with more than 400 companies behind the UK and Germany ¾¾ First producer of medicines in Europe with 220 prod

DocID: 1vq6b - View Document

Biotechnology Consultation Agency Response Letter BNF

Biotechnology Consultation Agency Response Letter BNF

DocID: 1vpUZ - View Document